September 13, 2017
Comella FDA Warning Letter Response

FDA Hammers A Flaunter of the Rules Against Making and Treating Patients with Fat Tissue-derived Stem Cells – Part Three

My original plan for this post series was going through the FDA’s Warning Letter issued to Ms. Comella, Chief Scientific Officer of the US Stem Cell Clinic (USSCC), on August 24th to review adverse findings the FDA published on the conditions and quality issues they found during their auditing visits. If you want to get...
Read More